Overview

Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Participants With Dementia With Lewy Bodies

Status:
Completed
Trial end date:
2020-04-15
Target enrollment:
Participant gender:
Summary
This study will be conducted to compare E2027 to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus (CIBIC-Plus) Caregiver Input in participants with dementia with Lewy bodies after 12 weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Eisai Inc.